/
MYGN
$5.85-$0.03 (-0.51%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$555.4M
94M shares
52-week range
$3.53 – $8.59
46% from low
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
CS
Borrow rate
0.42%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-24.73
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $851.1M | $638.6M | $557.0M | $690.6M | $678.4M | $753.2M | $837.6M | $824.5M |
| Cost of revenue | $201.0M | $186.1M | $178.2M | $197.6M | $202.0M | $236.2M | $252.2M | $247.9M |
| Gross profit | $650.1M | $452.5M | $378.8M | $493.0M | $476.4M | $517.0M | $585.4M | $576.6M |
| Gross margin | 76.4% | 70.9% | 68.0% | 71.4% | 70.2% | 68.6% | 69.9% | 69.9% |
| R&D | $85.9M | $77.2M | $80.9M | $81.9M | $85.4M | $88.7M | $113.4M | $106.8M |
| Operating income | $7.6M | −$231.7M | −$194.8M | −$190.5M | −$140.6M | −$257.4M | −$123.5M | −$67.8M |
| EBITDA | $85.0M | −$140.5M | −$123.4M | $12.3M | −$84.7M | −$197.4M | −$59.5M | −$330.9M |
| Net income | $4.6M | −$199.5M | −$223.7M | −$27.2M | −$112.0M | −$263.3M | −$127.3M | −$365.9M |
| Net margin | 0.5% | -31.2% | -40.2% | -3.9% | -16.5% | -35.0% | -15.2% | -44.4% |
| EPS (diluted) | 0.06 | -2.69 | -2.99 | -0.35 | -1.39 | -3.18 | -1.41 | -3.96 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $864M | $0.06 | $-0.37–$0.55 | 5 |
| 2027 | $916M | $0.15 | $0.04–$0.33 | 5 |
| 2028 | $970M | $0.27 | $0.26–$0.28 | 2 |
| 2029 | $1.1B | $0.57 | $0.56–$0.58 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Myriad Genetics Inc
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
www.myriad.com- Employees
- 2,700
- IPO / List date
- Oct 6, 1995
- HQ
- SALT LAKE CITY, UT
Held by traders on TradeandTell
No one on the platform currently holds MYGN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 454,374 | $2.0M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2009-03-26 | 2-for-1 |
Recent trades on TradeandTell
No one on the platform has traded MYGN yet.
